Editor's Note: Green and red arrows refer to intraday stock price movement.NEW YORK ( TheStreet) -- CHANGE IN RATINGS Auxilium Pharmaceuticals ( AUXL) rated new Buy at UBS. $30 price target. The company's two lead products are underappreciated by the market. CH Robinson ( CHRW) upgraded at Deutsche from Hold to Buy, Deutsche Bank said. $86 price target. Company is leveraged to tighter trucking capacity. Cisco Systems ( CSCO) downgraded at Auriga from Buy to Hold, Auriga USA said. $19 price target. Company is likely to face increased competition in the coming quarters. CVR Energy ( CVI) initiated at Credit Suisse with an Outperform rating and $30 price target. Strong earnings power not priced in, Credit Suisse said. Dr. Pepper Snapple ( DPS) downgraded at Deutsche from Buy to Hold, Deutsche Bank said. Valuation call, as the company lacks near-term catalysts. $40 price target. FirstEnergy ( FE) upgraded at Jefferies from Underperform to Hold. $38 price target. Expect the company to maintain its investment grade rating. Finish Line ( FINL) upgraded at Citigroup to Buy from Hold. Margin expansion on strong footwear cycle. Price target increased to $25 from $22. Fifth Third ( FITB) upgraded at Baird from Neutral to Outperform, Robert Baird said. $17 price target. Large-cap banks appear oversold and the stock is trading at just 9x expected 2012 earnings. Google ( GOOG) downgraded at Credit Suisse to Hold from Buy as it is now a "show-me story," Credit Suisse said. Price target lowered to $650 from $750. Hasbro ( HAS) upgraded at Morgan Joseph from Hold to Buy, Morgan Joseph said. $54 price target. Company has handled its inventory issues and has several potential near-term catalysts. Hasbro ( HAS) estimates, target lowered at Goldman. Shares of HAS now seen reaching $58, according to Goldman Sachs. Estimates also cut, as the company is realizing higher costs from its TV venture. Buy rating. Harley-Davidson ( HOG) upgraded at Goldman from Sell to Neutral, Goldman Sachs said. $44 price target. Domestic bike demand is stabilizing. Impax Labs ( IPXL) rated new Neutral at UBS. $30 price target. Company is facing increased generic competition. Rosetta Resources ( ROSE) upgraded at Canaccord to Buy, Canaccord Genuity said. Valuation call, based on a $53 price target.